The Russian Direct Investment Fund (RDIF) closed a agreement with the Serum Institute of India (SII), the world’s largest vaccine manufacturer, to produce 300 million annual doses of Sputnik V vaccine against coronavirus. The first doses would be ready in September.
“This strategic partnership is an important step in significantly increasing our production capacity,” said Kirill Dmitriev, president of the RDIF, which funded the development of the Sputnik V vaccine.
In a statement, Dmitriev stated that the first doses produced by IBS will arrive in September Y “the process of technological exchange is already well advanced”.
The president of the RDIF explained that the SII has already received “cell and vector samples” sent by the Gamaleya Institute – creator of Sputnik V – to begin production.
According to Adar Poonawalla, head of IBS, “it is essential that the Russian vaccine is available to all people in India and around the world,” the AFP news agency reported.
India is the largest and most populous country with which Russia signed agreements to produce Sputnik V and, in addition, it is one of the countries most affected by the coronavirus. In addition, IBS produces other vaccines against coronavirus, such as AstraZeneca’s.
Dmitriev stressed that Russia already has agreements with more than twenty countries for the production of Sputnik V, including Argentina. This vaccine, detailed from the RDIF, has already received the approval of 67 countries, in which a total of 3.5 billion people live.
The vaccine created in Russia was received with some skepticism by some countries, especially the United States, although its effectiveness has already been proven by research published in the scientific journal The Lancet.